{"id":"bilastine-0-6","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dry mouth"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bilastine selectively and competitively inhibits peripheral H1-receptors, which are involved in the mediation of allergic reactions. This results in the relief of symptoms associated with allergic conditions such as itching, sneezing, runny nose, and watery eyes.","oneSentence":"Bilastine is an antihistamine that works by blocking the action of histamine, a substance in the body that causes allergy symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:58:12.728Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal and perennial allergic rhinitis"},{"name":"Chronic idiopathic urticaria"}]},"trialDetails":[{"nctId":"NCT04810390","phase":"PHASE3","title":"Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2021-03-26","conditions":"Allergic Conjunctivitis","enrollment":59},{"nctId":"NCT03479307","phase":"PHASE3","title":"A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2018-04-07","conditions":"Allergic Conjunctivitis","enrollment":228},{"nctId":"NCT03231969","phase":"PHASE2","title":"A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2017-07-20","conditions":"Allergic Conjunctivitis","enrollment":121}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Bilastine 0.6%","genericName":"Bilastine 0.6%","companyName":"Faes Farma, S.A.","companyId":"faes-farma-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bilastine 0.6% is an ophthalmic solution used to treat allergic conjunctivitis. It works as a small molecule histamine H1 receptor inverse agonist.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}